The Food and Drug Administration (FDA) published the final guidance for industry entitled “Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs.” This guidance finalizes the draft guidance for industry of the same title issued on October 21, 2022.